Global retrospective study comparing consolidation ALK tyrosine kinase inhibitors (TKI) to durvalumab (durva) or observation (obs) after chemoradiation (CRT) in unresectable locally-advanced ALK+ non-small cell lung cancer (NSCLC).

医学 杜瓦卢马布 酪氨酸激酶 癌症研究 酪氨酸激酶抑制剂 内科学 肺癌 肿瘤科 非小细胞肺癌 间变性淋巴瘤激酶 病理 癌症 无容量 受体 免疫疗法 恶性胸腔积液 A549电池
作者
Ritujith Jayakrishnan,Amin H. Nassar,Frances A. Shepherd,Jessica J. Lin,Steven H. Lin,Purnima Shakya,Thomas J. Dilling,Jair Bar,Christian Grohé,Shruti Gupta,Bailey Fitzgerald,Elio Adib,K. Nathan Sankar,Joel W. Neal,Helena A. Yu,Ryan M. Whitaker,Ana I. Velazquez Mañana,Abdul Rafeh Naqash,Sarah B. Goldberg,So Yeon Kim
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:42 (16_suppl): 8013-8013
标识
DOI:10.1200/jco.2024.42.16_suppl.8013
摘要

8013 Background: For patients (pts) with unresectable locally-advanced NSCLC, standard of care involves durva consolidation after concurrent CRT, although its benefit in ALK+ tumors is unclear. The ALINA trial demonstrated adjuvant efficacy of alectinib in resected ALK+ NSCLC, but the optimal consolidation strategy for unresectable locally-advanced ALK+ NSCLC remains elusive. Methods: This multi-institutional international retrospective analysis included pts with stage III unresectable ALK+ NSCLC who received an ALK TKI, durva, or obs alone after concurrent CRT between 2015-2022. Baseline characteristics of age, sex, smoking history, and PD-L1 status were collected. Clinical outcomes including real-world progression-free survival (rw-PFS), overall survival (OS), and treatment-related adverse events (trAE) as defined using CTCAE 5.0 were assessed, and multivariate cox regression models were performed. Results: Sixty-four pts across 16 institutions were included. The median age was 57 (IQR 49-66) and 61% were females. The majority had adenocarcinoma (97%) and had never smoked (58%). 15 received ALK TKI (10 alectinib, 3 crizotinib, 1 brigatinib, 1 lorlatinib), 30 received durva, and 19 received obs alone. There was no significant difference in stage of cancer (IIIA, B, or C) or PD-L1 status among groups. After adjusting for stage and age at CRT initiation, median rw-PFS was significantly longer for ALK TKI (rw-PFS not reached [NR], 95% CI 22.7-NR) vs durva (11.3 months (mo), 95% CI 9.2-18.5, p= 0.005, HR = 0.12) or obs (7.4 mo, 95% CI 3.4-12.5, p < 0.0001). Two (13%) pts progressed on ALK TKI. 25 pts (83%) progressed on durva leading to treatment with ALK TKI in 23, and 18 (95%) progressed while under obs leading to treatment with ALK TKI in 15. 3-year OS was 100% for ALK TKI vs 90.5% for durva vs 63.5% for obs. Median OS was NR (95% CI NR-NR) for both ALK TKI and durva vs 70.6 mo (24.9-NR) in the obs group ( p= 0.03 for both ALK TKI and durva compared to obs). Median duration of therapy was 24.7 mo with ALK TKI and 6.5 mo with durva. Grade ≥3 trAE occurred in 27%, 7%, 6% of pts treated with ALK TKI (1 fatigue, 1 diarrhea, 1 hyperbilirubinemia, 1 pneumonitis), durva (1 fatigue, 1 neutropenia), and obs (1 neutropenia) respectively. Treatment discontinuation due to toxicity occurred in 4 (27%) with ALK TKI and in 3 (10%) with durva. Conclusions: In this retrospective study of stage III ALK+ NSCLC, consolidation ALK TKI demonstrated clinically meaningful improvement in PFS and OS over durva and obs, while showing a slightly higher rate of trAE over dura and obs. Furthermore, we show a high rate of progression following CRT alone in ALK+ NSCLC. These findings underscore the need for prospective molecularly driven trials to determine the optimal consolidation therapy for unresectable ALK+ NSCLC.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
zycdx3906完成签到,获得积分10
4秒前
闹心应助小小绿采纳,获得50
5秒前
尧九完成签到,获得积分10
5秒前
123完成签到 ,获得积分10
5秒前
6秒前
zhouleiwang完成签到,获得积分10
7秒前
摘星012发布了新的文献求助20
7秒前
嘿嘿完成签到,获得积分10
10秒前
yr完成签到 ,获得积分10
11秒前
11秒前
王道远完成签到,获得积分10
11秒前
Jasper应助zhouleiwang采纳,获得10
11秒前
123完成签到,获得积分10
12秒前
虎妞完成签到 ,获得积分10
12秒前
积极晓绿完成签到,获得积分10
12秒前
EaRnn发布了新的文献求助10
13秒前
现代的卿完成签到 ,获得积分10
13秒前
拉长的服饰完成签到,获得积分10
14秒前
香菜大王完成签到 ,获得积分10
14秒前
14秒前
愉快静曼发布了新的文献求助10
14秒前
奋斗人雄完成签到,获得积分10
16秒前
小v完成签到 ,获得积分10
16秒前
Gigi完成签到,获得积分10
17秒前
ssssssssci完成签到,获得积分10
17秒前
Owen应助大气灵枫采纳,获得10
18秒前
独特乘风完成签到,获得积分10
21秒前
含糊的代丝完成签到 ,获得积分10
24秒前
朴素的紫安完成签到 ,获得积分10
25秒前
yyj完成签到,获得积分10
26秒前
27秒前
27秒前
量子星尘发布了新的文献求助10
27秒前
君临完成签到,获得积分10
27秒前
林早上完成签到,获得积分20
27秒前
xiu完成签到 ,获得积分10
28秒前
栗爷完成签到,获得积分0
28秒前
深年完成签到,获得积分10
29秒前
求知若渴完成签到,获得积分0
29秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
Research on Disturbance Rejection Control Algorithm for Aerial Operation Robots 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038388
求助须知:如何正确求助?哪些是违规求助? 3576106
关于积分的说明 11374447
捐赠科研通 3305798
什么是DOI,文献DOI怎么找? 1819322
邀请新用户注册赠送积分活动 892672
科研通“疑难数据库(出版商)”最低求助积分说明 815029